



medibank

# 2022 full year results

Investor presentation

18 August 2022

**David Koczkar** – Chief Executive Officer

**Mark Rogers** – Group Executive  
Chief Financial Officer & Group Strategy

# Important notice

The information contained in this presentation is general information only. The information contained in this presentation is not investment or financial product advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. To the extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by Medibank Private Limited ("MPL") or any of its related bodies corporate. No representation or warranty, express or implied, is made by any person, including MPL, and its related bodies corporate, directors, officers, employees, professional advisors and agents ("Related Parties") as to the fairness, accuracy, completeness, reliability or correctness of the information, opinions and conclusions contained in this presentation.

An investment in MPL securities is subject to investment and other known and unknown risks, some of which are beyond the control of MPL, such as general economic conditions in Australia, exchange rates, the market environment in which MPL operates and inherent regulatory risks in MPL's business. MPL does not guarantee any particular rate of return or the performance of MPL securities.

Past performance information in this presentation is given for illustrative purposes only. It is not, and should not be relied upon as, an indication of future performance.

This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of MPL and associated entities and certain plans and objectives of the management of MPL. Forward-looking statements can be identified by the use of forward-looking terminology, including without limitation the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "aspiration", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts.

Such forward-looking statements are not guarantees or predictions of future performance and are based on information, expectations and assumptions as at the date of this presentation regarding MPL's present and future business strategies and the future political, regulatory and economic environment in which MPL will operate.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors. The nature of such factors may cause the actual results or performance of MPL to be materially different from the results or performance expressed or implied by such forward-looking statements. No representation or warranty is made that any of these statements or forecasts (express or implied) will come to pass or that any forecast result will be achieved.

To the full extent permitted by law, MPL and its Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including but not limited to any assumptions or expectations set out in the presentation).

All figures in the presentation are in Australian dollars unless stated otherwise and all market shares are estimates only. Some figures, amounts, percentages, estimates, calculations of value and fractions are subject to rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this presentation. Further, some balances subject to rounding may not add consistently throughout this presentation.

The distribution of this presentation, including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. Nothing in this presentation constitutes an offer or invitation to issue or sell securities, or a recommendation to subscribe for or acquire securities, by or on behalf of MPL, its related bodies corporate or any other person in any jurisdiction including where it is unlawful to do so. This presentation is not and does not constitute an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released, directly or indirectly, in the United States.

Abbreviations and acronyms used throughout the presentation may be found in the glossary.

This presentation should be read in conjunction with MPL's other periodic and continuous disclosure announcements lodged with the ASX or released on the MPL's website, including without limitation its Appendix 4E and Financial Report for the year ended 30 June 2022, which are available at [www.medibank.com.au](http://www.medibank.com.au).

## Acknowledgment of Country

Medibank acknowledges Aboriginal and Torres Strait Islander peoples as the First Peoples of this nation.

We proudly recognise Elders past, present and emerging as the Traditional Owners and Custodians of the lands on which we work and live.

We're committed to supporting self-determination and envision a future where all Australians embrace Aboriginal and Torres Strait Islander histories, cultures and rights as a central part of our national identity.



medibank

# Highlights

**David Koczkar**  
Chief Executive Officer

# FY22 highlights

We continue to deliver for our customers

## Experience



Maintaining high levels of **customer advocacy**<sup>1</sup>

**45.3** (+8.2) Medibank

**42.4** (-0.6) ahm

c. **1.4m** (+12%)

customers registered for **My Medibank app**,

with c. **23%** growth in claims made through the app

c. **504k**

**health cover check ins**

## Value



c. **\$682m**

**total COVID-19 financial support package** to date

**Lowest average premium increase**



in **21 years**

c. **\$31.2m**



out-of-pocket savings through **Members' Choice Advantage** network

## Health



c. **568k** (+55%)

customers engaged with **Live Better** and **preventative programs**<sup>2</sup>

c. **27%**

of Medibank customers admitted to hospital were **supported by Health Concierge program** (FY21 c. 20%)

c. **3.5m**

**virtual health interactions**

<sup>1</sup> Average service NPS

<sup>2</sup> Includes total customers who have engaged with our preventative health offering, including Live Better Rewards, Live Better Activities, preventative health programs and any new offerings developed

# FY22 financial results summary

Strong result reflects growth across our business alongside ongoing cost discipline

## Customer outcomes



**+60.9k** (+3.2%)  
reported net resident  
policyholder growth

**+5.8k**  
reported net resident  
policyholder growth  
in July 2022

**\$5.7b** (+1.9%)  
customer claims<sup>1</sup>

## Key financial metrics



**7.4%** (-30bps)  
Health Insurance  
underlying management expense ratio  
(reported MER 7.8%)

**\$592.6m** (+10.0%)  
Health Insurance  
operating profit

**\$45.5m** (+44.9%)  
Medibank Health  
segment profit

**-\$24.8m**  
down from \$120m in FY21  
net investment income / loss

**\$393.9m** (-10.7%)  
NPAT

**7.3cps** (+5.8%)  
Final ordinary dividend fully franked

**13.4cps** (+5.5%)  
FY22 ordinary dividend fully franked


# Sentiment towards health will support industry growth

Participation remains strong as affordability and value become increasingly important to Australians

## Industry participation remains strong

- Seven consecutive quarters of growth<sup>1</sup>
  - Driven by younger and new to industry joins – positive signs for industry sustainability
- Consumer trends support continued growth, albeit at a slower rate
  - Sentiment towards health
  - Increasing net migration


### Quarterly industry policyholder growth<sup>1</sup>



## Consumers seeing more value in PHI

- Highest level of industry retention in 10 years<sup>1,5</sup>
- Access to healthcare remains a priority for consumers, especially with public system under considerable strain<sup>2</sup>
- Focus on affordability is key
  - Household savings generated during COVID can offset near term financial headwinds<sup>3</sup>
  - Premium increases relative to wage growth and strong employment support retention
  - Low premium increases and COVID givebacks support affordability


### Premium increase, wage growth and industry growth<sup>1,5</sup>



## Health spending is less discretionary

- Consumers are spending more on their health than pre-pandemic and this trend is expected to continue<sup>4,6</sup>
- Customers are more likely to hold onto their insurance and reduce spend in other areas<sup>7</sup>
- The proportion of customers intending to drop PHI declining to the lowest level in 5 years<sup>8</sup>

### Average household spending index<sup>6</sup>



<sup>1</sup> APRA quarterly private health insurance statistics. Updated May 2022

<sup>2</sup> Medibank research – Brand Survey Tracker on attitude to PHI

<sup>3</sup> Speech by RBA Deputy Governor. How Are Households Placed for Interest Rate Increases? Updated July 2022

<sup>4</sup> Mc Kinsey & Company. Emerging cautiously: Australian consumers in 2022. Updated July 2022

<sup>5</sup> FY22 policyholder growth and wage growth are to March 2022. Policyholder growth data from APRA and PHIAAC. Average annual price changes in private health insurance premiums from the Department of Health. Wage price index from ABS

<sup>6</sup> ABS. Monthly household spending, current price. Updated May 2022. Annual numbers are average of monthly figures and indexed to 2019. 2022 is May 2022 YTD

<sup>7</sup> Medibank research – consumer tracking, generation and population weighted, n = 727. Updated July 2022

<sup>8</sup> Medibank research – monthly brand survey. Updated June 2022

# There are challenges in the delivery of healthcare

The industry needs to act to create a health system fit for the future

## Immediate challenges accelerate the need for our industry to act

- Costs are rising through inflationary pressure
- Australia's health system is under stress
  - Elective surgery backlog continues to escalate and unlikely to reduce soon
  - Workforce challenges affecting the entire health system

## Opportunities exist to increase affordability and efficiency

- Low current uptake of prevention and new care settings (e.g. homecare or short stay)
  - \$38b+ spent on care for people with chronic health conditions per year<sup>1</sup>
  - Australia is behind OECD peers<sup>2</sup> in adoption of new care settings
- Healthcare lagging other industries in productivity<sup>3</sup>
  - Industry collaboration is needed to drive productivity to achieve benefits for consumers
  - Medibank's strength – delivering c. \$100m productivity over 5 years and achieving industry leading MER
- The need to progress the reform agenda
  - Prostheses reforms (c. \$900m cumulative savings over 4 years<sup>4</sup>) – an encouraging start

Median waiting time for elective surgery and % admitted within recommended time for public hospitals<sup>5</sup>



|                                                     |                       | Short stay model                                      |                  |                                    |                   |
|-----------------------------------------------------|-----------------------|-------------------------------------------------------|------------------|------------------------------------|-------------------|
|                                                     |                       | % performed as day cases <sup>2</sup>                 |                  | Potential length of stay reduction |                   |
|                                                     | Total procedures p.a. | Cost per procedure (traditional setting) <sup>7</sup> | Australia        | International example              |                   |
| Laparoscopic cholecystectomy (Gall bladder surgery) | c. 50k <sup>6</sup>   | \$7.4k                                                | 4% Australia     | c. 57% Canada                      | 50% <sup>8</sup>  |
| Hernia procedures                                   | c. 40k <sup>9</sup>   | c. \$5.4k                                             | c. 27% Australia | c. 85% Denmark                     | 50% <sup>10</sup> |

1 Productivity Commission - Targeted texts and peer support: how smarter health care can cut costs and help Australians with chronic conditions. Updated April 2021

2 OECD statistics across inguinal hernia, cholecystectomy, tonsils and adenoids, septoplasty. Updated July 2022

3 Mc Kinsey & Company analysis. Labour productivity growth was approximated as the industry gross value added CAGR minus the employment by industry CAGR

4 The Hon Greg Hunt, Minister for Health and Aged Care, 17 March 2022. Reforms to deliver lower prices for medical devices and lower private health insurance premiums (Media release)

5 AMA analysis of Australian Institute of Health and Welfare (AIHW) data. Updated May 2022

6 Australian Commission on safety and quality in healthcare. Laparoscopic cholecystectomy hospitalisations in 2014-15

7 How much will my procedure cost? by Medibank Hospital Assist. Updated July 2022

8 Wichmann et al. Laparoscopic cholecystectomy - comparison of early postoperative results in an Australian rural centre and a German university hospital. 2010. Median length of stay in Australia is 1 day

9 Department of Health - Victoria State Government. Better Health Channel - hernias. Updated August 2022

10 Overnight discharge to same day discharge. Mills J. et al. Same-day inguinal hernia repair in Australia, 2000-19

# Megatrends in health will drive sustainable patient-centric outcomes

Industry fundamentals are changing



## Consumerisation of health



## The shift to prevention



## The rise of new care settings



## Outcome-based care

|                       |                                                                                                                                                                                                              |                                                                                                                            |                                                                                                                                                                                                                                  |                                                                                                                                                                                                          |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Historic state</b> | Passive approach to receiving care                                                                                                                                                                           | Treating preventable disease                                                                                               | Standard care pathways that do not consider patients' individual needs                                                                                                                                                           | Disconnected and transaction-based models of care                                                                                                                                                        |
| <b>Future state</b>   | A shift in focus on individual health and personal needs                                                                                                                                                     | Focus on better managing and preventing diseases through health engagement and prevention programs                         | New care settings that deliver quality care at lower costs, giving patients and providers more choice and value                                                                                                                  | A connected system for patients, providers and our communities where incentives are aligned to health outcomes                                                                                           |
| <b>Opportunities</b>  | <p>Embedding technology solutions to personalise health experiences and improve choice and navigation e.g. digital concierge</p> <p>Rapid adoption of virtual care options e.g. Better Minds hub and app</p> | Preventative health spend expected to increase from <2% of Australia's total health expenditure to 5% by 2030 <sup>1</sup> | <p>Greater adoption of Medibank's short stay, no gap program could save 217k bed days and \$102m in out-of-pocket costs in 2030<sup>2</sup></p> <p>Emerging trend in rehab with a shift from acute settings to rehab at home</p> | <p>Working with hospitals on a broader set of outcomes, including customer experience KPIs</p> <p>Incentives for better care, e.g. the Practice Incentives Program for GPs by the Federal Government</p> |

<sup>1</sup> Australian Institute of Health and Welfare - Disparities in potentially preventable hospitalisations across Australia, 2012-13 to 2017-18. Updated 2020

<sup>2</sup> KPMG. Medibank facilitates a sustainable healthcare system. July 2022

# Our strategy

Growing as a health company

## Deliver leading experiences



---

Create personalised and connected customer experiences

Empower our people

Collaborate with our communities to make a difference

## Differentiate our insurance business



---

Deliver more value, choice and control for customers

Offer products and services to meet all customer needs

Leverage our dual brands and provider networks

## Expand in health



---

Focus growth on prevention and integrated care models

Scale and connect our health businesses

Bring benefits back to our core

## Better Health for Better Lives

## FY22 key achievements

### Personalised and connected customer experiences

- Created a digital health ecosystem with the integration of Live Better and My Medibank
- Greater data insights enabled better conversations with customers on their cover and health needs
- Simplified service experience – c. 42% of Medibank customer service interactions were through self-serve channels (FY21: c. 38%)

### Our people

- Maintained an engaged workforce, supported by the successful launch of our 2030 Vision and refreshed values
- Embedded Future Fit way of flexible working model

### Our community

- Continued to progress ESG strategy, including setting robust short, medium and long-term Net Zero targets<sup>1</sup>
- Launched We Are Lonely Podcast as part of our 10-year commitment to loneliness – reaching c. 55k listeners

## FY23 focus

- Create a personalised digital gateway between our customers and health services
- Enhance the breadth and depth of My Medibank to deliver seamless PHI and health experience
- Improve ahm customer experience through expansion of digital and self-guided service tools
- Further embed 2030 Vision and refreshed employee values to drive employee engagement and advocacy
- Design unique employee value proposition to further strengthen talent attraction and retention
- Achieve milestones set out in our 5th Reconciliation Action Plan and 2nd Accessibility and Inclusion Plan
- Continue with Net Zero targets and pathway
- Progress 10-year Loneliness strategy, including We Are Lonely podcast, external partnerships and research

### Milestones

#### Customer advocacy: Service NPS (average)

|          | FY22 | FY23 benchmark <sup>2</sup> |
|----------|------|-----------------------------|
| Medibank | 45.3 | >35                         |
| ahm      | 42.4 | >35                         |

#### Employee advocacy: eNPS

|                       | FY22 | FY23 benchmark <sup>3</sup> |
|-----------------------|------|-----------------------------|
| Place to work         | +27  | ≥+26                        |
| Products and services | +29  | ≥+19                        |

<sup>1</sup> See slide 33 - Summary of sustainability achievements and progress. Updates on Net Zero targets and further details on ESG strategy and targets are included in 2022 Sustainability Report to be published in September 2022

<sup>2</sup> Benchmark reflects sustaining service levels while continuing to digitise the service delivery model

<sup>3</sup> FY23 benchmark for Place to Work eNPS based on global average benchmark, Products and Services eNPS target based on historical trend

# Differentiate our insurance business

## FY22 key achievements

### High quality growth in both brands

- New to industry and young cohorts c. 70% of new joins
- Growth in corporate and non-resident markets supported by competitive and targeted offerings
- Maintained industry leading MER - 10bps MER improvement to 7.8% (industry average: 9.6%)<sup>1</sup>

### Improved engagement with customers

- Downgrading of 60bps in the resident book – the lowest in 10 years
- Improved lapse performance compared to 2H21
- Increased loyalty among customers engaging with Live Better and holding multiple products

### Expanded products and network

- Medibank My Choice extras and ahm choosable extras well-received by customers
- Expanded Members' Choice Advantage to 5 additional modalities<sup>2</sup>
  - Nearly doubling our network to c. 2.6k locations
  - Covering more service types than other PHIs
  - Customers can experience lower or no out-of-pocket costs

## FY23 focus

- Our customer first approach continues to be the foundation for differentiation and growth
- Continue to target growth in corporate, overseas and regional markets
- Enhance our relationship review program
- Use Live Better Rewards to drive acquisition, engagement and value
- Further personalise customer experiences - connecting them with relevant products and services in health
- Deepen provider relationships to provide more value to customers

## Milestones

### Market share<sup>1</sup> – Updated for FY23

#### Q3FY22

27.35% (+4bps since FY21)

#### FY25 aspiration

up 25-75bps on FY22

### Health Insurance productivity delivered

#### FY22

c. \$15m

#### FY22 – FY24 target

\$40m including c. \$15m delivered in FY22

<sup>1</sup> APRA PHI quarterly data to March-22. Industry MER is 12-month to March 22

<sup>2</sup> From July 2022, Members' Choice Advantage network will expand to include physio, chiro, podiatry, acupuncture and remedial massage

## FY22 key achievements

### Prevention and integrated care models

- Strong uptake in prevention and health and wellbeing
  - 10k+ customers enrolled in preventative programs (+40%)
  - Scaled Live Better Rewards (+73% in size) with high engagement
- Progress in mental health solutions
  - Better Minds attracted c. 79k users and app downloads
  - Piloted telepsych clinic, partnering with Myhealth and Medinet
  - Partnered to deliver out-of-hospital care for mental health

### Our health businesses and investments

- Myhealth expanded to 106 clinics, with a strong expansion pipeline in FY23
- \$10m investment in health tech company Medinet
- Restructured our telehealth business to align with our strategy
- COVID Care at Home by Calvary-Medibank JV supported c. 165k patients in 4 states

### Bring benefits back to our core

- Amplar's prioritising services directly to Medibank
  - 87.3k interactions with Medibank customers
  - 1 in 4 Medibank patients undergoing joint replacements have rehab at home
- More than doubled no gap network (including short stay) across 7 states and territories - accessible to nearly 64% of Medibank customers by October 2022<sup>1</sup>

## FY23 focus

- Scale preventative programs and Live Better
- Develop virtual primary allied health services including physiotherapy and dietetics
- Expand health concierge, including support for acute mental health admission
- Support Myhealth's growth with analytics and participation in prevention programs
- Grow homecare with the recovery of hospital admission volumes
- Expand out-of-hospital models of care for mental health
- Scale no gap program to grow a national network for joint replacement, endoscopy, and some general surgery procedures
- Deliver new public system digital triage services in two regions

## Milestones

### Medibank Health segment profit

| FY22    | FY23-FY25 target                                                                                                                                                                              |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| \$45.5m | Average at least 15% p.a. organic segment profit growth<br>Aim to invest \$150m - \$250m in total to grow Medibank Health inorganically as suitable opportunities arise over the next 3 years |

### Health and wellbeing

|                                                | FY22  | FY25 target |
|------------------------------------------------|-------|-------------|
| Live Better Rewards participants               | 522k  | 800k        |
| Preventative program participants <sup>2</sup> | c.10k | > 50k       |

<sup>1</sup> Medibank customers live within 25km of a no gap site

<sup>2</sup> Includes total customers who have engaged with 8 preventative health programs (e.g. Better knee, better me, Better Hip) and any new offerings developed



medibank

# Financial results

**Mark Rogers** – Group Executive  
Chief Financial Officer  
& Group Strategy

# Group financial summary

Medibank Health has made a significant contribution to Group operating profit growth

| Financial year ended 30 June (\$m)           | 2021           | 2022           | Change         |
|----------------------------------------------|----------------|----------------|----------------|
| <b>Group revenue from external customers</b> | <b>6,910.4</b> | <b>7,128.5</b> | <b>3.2%</b>    |
| Health Insurance operating profit            | 538.6          | 592.6          | 10.0%          |
| Medibank Health segment profit               | 31.4           | 45.5           | 44.9%          |
| <b>Segment operating profit</b>              | <b>570.0</b>   | <b>638.1</b>   | <b>11.9%</b>   |
| Corporate overheads                          | (41.7)         | (44.0)         | 5.5%           |
| <b>Group operating profit</b>                | <b>528.3</b>   | <b>594.1</b>   | <b>12.5%</b>   |
| Net investment income/(expense)              | 120.0          | (24.8)         | n.m.           |
| Amortisation of intangibles                  | (4.6)          | (2.0)          | (56.5%)        |
| Other income/(expenses)                      | (11.4)         | (7.3)          | (36.0%)        |
| <b>Profit before tax</b>                     | <b>632.3</b>   | <b>560.0</b>   | <b>(11.4%)</b> |
| Income tax expense                           | (191.1)        | (166.1)        | (13.1%)        |
| <b>NPAT</b>                                  | <b>441.2</b>   | <b>393.9</b>   | <b>(10.7%)</b> |
| Effective tax rate                           | 30.2%          | 29.7%          | (50bps)        |
| EPS (cents)                                  | 16.0           | 14.3           | (10.7%)        |
| Normalisation for growth asset returns       | (31.2)         | 22.7           | n.m.           |
| Normalisation for defensive asset returns    | (11.3)         | 18.5           | n.m.           |
| <b>Underlying NPAT</b>                       | <b>398.7</b>   | <b>435.1</b>   | <b>9.1%</b>    |
| Underlying EPS (cents)                       | 14.5           | 15.8           | 9.1%           |
| <b>Dividend per share (cents)</b>            | <b>12.7</b>    | <b>13.4</b>    | <b>5.5%</b>    |
| Dividend payout ratio <sup>1</sup>           | 87.7%          | 84.8%          | (3.3%)         |

- Group operating profit up 12.5%
  - Meaningful growth contribution from Medibank Health
  - Net investment income loss of \$24.8m compared to a gain of \$120.0m in FY21
  - NPAT down 10.7%
- Net investment income loss of \$24.8m reflecting volatile Australian and global equities performance
- Amortisation charge continues to decline with intangibles balances largely amortised
- Improvement in other income / (expenses) reflects lower M&A spend
- Effective tax rate 29.7%
  - Non-deductible expenses in FY21
  - Expect similar rate in FY23
- Underlying EPS up 9.1% to 15.8c
  - Adjusted for normalisation of investment returns (1.5c per share)
  - Reported EPS down 10.7% to 14.3c per share


<sup>1</sup> Dividend payout ratio based on Underlying NPAT

# COVID-19 impacts – claims recovery

Claims remain below underlying expectations, deferred claims liability continues to increase


## Private hospital claims<sup>1</sup>

12-month rolling to May 22 \$ growth vs pre-COVID-19 period<sup>2</sup>



## Private hospital non-surgical claims

12-month rolling to May 22 \$ growth vs pre-COVID-19 period<sup>2</sup>



## Total<sup>3</sup>

- Vic/NSW down 7% (1H22: 0%), other states down 2% (1H22: +4%)
- Staff shortages and restrictions have impacted claims recovery

## Surgical

- Vic/NSW down 5% (1H22: +3%), other states down 1% (1H22: +6%)
- Stronger rebound in same day claims, with restrictions biased towards overnight procedures

## Non-surgical

- Vic/NSW down 11% (1H22: -5%), other states down 6% (1H22: -2%)
- Notable declines across rehab and respiratory (c.29% of non-surgical benefits)
- Rehab annual spend c. 22% of non-surgical claims nationally and down on average c. 15% relative to surgical claims volumes
- Increasing likelihood softness in rehab will become a permanent trend

## Updates to assumptions

- Average Hospital deferral assumption of 55% (1H22: 61%)
  - Surgical claims deferral assumptions unchanged at 85%
  - Non-surgical reduced from 50% to 40% during 2H22
- Deferred claims liability increased \$224.5m to \$448.3m (1H22: \$328.7m)
- Pre-COVID-19 private hospital claims comprised
  - 59% in Victoria/NSW and 41% in other states
  - c. 57% surgical and c. 43% non-surgical
- Expect it will take c. 24 months for deferred procedures to be completed

<sup>1</sup> Private hospital services incurred by Medibank Group excluding prostheses and medical

<sup>2</sup> Pre COVID-19 period is the 12-month period from March 2019 to February 2020. Claims figures for this period have been adjusted for inflation

<sup>3</sup> 1H22 figures refer to 12-month rolling period to Nov 21 \$ growth vs pre-COVID-19 period as reported at 1H22

# Health Insurance result

Continued strength in the resident business partially offset by closed borders impacting the non-resident business

| Financial year ended 30 June (\$m) | 2021      | 2022      | Change  |
|------------------------------------|-----------|-----------|---------|
| Premium revenue                    | 6,680.3   | 6,859.8   | 2.7%    |
| Claims expense                     | (5,586.2) | (5,695.0) | 1.9%    |
| Risk equalisation                  | (24.6)    | (36.1)    | 46.7%   |
| Net claims expense                 | (5,610.8) | (5,731.1) | 2.1%    |
| Gross profit                       | 1,069.5   | 1,128.7   | 5.5%    |
| Management expenses                | (530.9)   | (536.1)   | 1.0%    |
| Operating profit                   | 538.6     | 592.6     | 10.0%   |
| Gross margin                       | 16.0%     | 16.5%     | 50bps   |
| MER                                | 7.9%      | 7.8%      | (10bps) |
| Operating margin                   | 8.1%      | 8.6%      | 50bps   |

| COVID-19 impact <sup>1</sup> | COVID-19 Adj. |
|------------------------------|---------------|
| 369.4                        | 7,229.2       |
| (368.8)                      | (6,099.9)     |
| 0.6                          | 593.2         |

## Major drivers of performance

- Strong resident policyholder growth
- Better than expected downgrading
- Continued cost discipline
- Benefits of increasing scale

## Risk equalisation payment increased \$11.5m

- ahm policyholder growth
- Lower than industry claims growth

## Modest COVID-19 impact on reported results of \$0.6m (FY21: \$3.0m)

- \$369.4m of customer support measures
- \$368.8m permanent claim savings

## Underlying performance

| Financial year ended 30 June (\$m) | 2021    | 2022    | Change  |
|------------------------------------|---------|---------|---------|
| Underlying revenue                 | 6,906.3 | 7,229.2 | 4.7%    |
| Reported gross profit              | 1,069.5 | 1,128.7 | 5.5%    |
| COVID-19 impact                    | 3.0     | 0.6     | (80.0%) |
| Underlying gross profit            | 1,072.5 | 1,129.3 | 5.3%    |
| Management expenses                | (530.9) | (536.1) | 1.0%    |
| Underlying operating profit        | 541.6   | 593.2   | 9.5%    |
| Underlying gross margin            | 15.5%   | 15.6%   | 10bps   |
| MER                                | 7.7%    | 7.4%    | (30bps) |
| Underlying operating margin        | 7.8%    | 8.2%    | 40bps   |

## Underlying gross profit up 5.3%

- Underlying revenue growth of 4.7%
- Continued subdued downgrading in 2H22
- Underlying gross margin up 10bps
- Achieved despite closed borders impacting non-resident profitability

## Underlying operating margin up 40bps to 8.2%

- Cost discipline
- Benefit of increasing scale
- Underlying MER improvement of 30bps

<sup>1</sup> FY22 COVID-19 adjustment of \$369.4m (FY21: \$226.0m) to revenue includes deferral of the 1 April 2022 premium increase and cash give back relating to Australian resident portfolio only. Permanent claims savings of \$368.8m (FY21: \$223.0m) as a result of COVID-19

# Health Insurance – policyholders

Strong resident policyholder growth of 3.2%

| Financial year ended 30 June (\$m)                 | 2021           | 2022           | Change          |
|----------------------------------------------------|----------------|----------------|-----------------|
| <b>Policyholders<sup>1</sup> (thousand):</b>       |                |                |                 |
| Opening balance                                    | 1,806.6        | 1,889.1        | 4.6%            |
| Acquisitions                                       | 221.2          | 223.0          | 0.8%            |
| Lapses                                             | (147.4)        | (162.1)        | 10.0%           |
| Net (suspensions)/reactivations                    | 8.7            | -              | n.m.            |
| <b>Closing balance</b>                             | <b>1,889.1</b> | <b>1,950.0</b> | <b>3.2%</b>     |
| - Medibank                                         | 1,417.8        | 1,444.4        | 1.9%            |
| - ahm                                              | 471.3          | 505.6          | 7.3%            |
| <b>Acquisition rate<sup>2</sup></b>                | <b>12.0%</b>   | <b>11.6%</b>   | <b>(40bps)</b>  |
| - Medibank                                         | 9.0%           | 9.3%           | 30bps           |
| - ahm                                              | 23.0%          | 19.7%          | (330bps)        |
| <b>Lapse rate<sup>2</sup></b>                      | <b>8.0%</b>    | <b>8.4%</b>    | <b>40bps</b>    |
| - Medibank                                         | 7.3%           | 7.4%           | 10bps           |
| - ahm                                              | 12.0%          | 12.7%          | 70bps           |
| <b>Policyholder growth</b>                         | <b>4.6%</b>    | <b>3.2%</b>    | <b>(140bps)</b> |
| <b>Total policy units<sup>1,3</sup> (thousand)</b> |                |                |                 |
| Closing balance                                    | 4,811.5        | 4,955.4        | 3.0%            |
| Average balance                                    | 4,763.1        | 4,867.1        | 2.2%            |

1 Consistent with reported industry data, policyholder numbers only include the resident portfolio whereas total policy units include both resident and non-resident portfolios

2 Transfers of policyholders between ahm and Medibank are excluded in consolidated lapse and acquisition rates but included at brand levels. Lapse and acquisition rates are based on the average of the opening and closing balances for the period

3 Refer to glossary for definition of policy units. Based on an average of the month-end balances over the reporting period

## PHI market industry remains buoyant

- Estimated 2.7% growth during FY22 including strong June quarter
- High quality growth including in new to industry and younger cohorts

## Policyholder numbers increased 3.2%

- Modest deterioration in acquisition and lapse rates largely reflecting favourable COVID-19 impacts in the prior period
- No notable change in suspension levels
- 2H22 lapse improvement vs pcip for both brands despite deteriorating economic conditions

## Medibank brand up 1.9%

- Acquisition rate up 30bps reflecting strong growth in corporate and digital
- 76% new to industry joins (FY21: 75%)
- Stable retention rate

## ahm brand up 7.3%

- Softer switching market continues
- 66% new to industry joins (FY21: 61%)
- Lower acquisition rate reflects lower sales through aggregators and increasing number of policyholders (>500k)
- More profitable direct sales which were more than 50% of total sales this period
- Limit roll over positively impacted retention in FY21
- Improved retention targeted through greater use of data insights and an improved experience for new customers

# Health Insurance – underlying resident claims

Underlying resident claims growth per policy unit declined 20bps to 2.3%

| Financial year ended 30 June (\$m) <sup>1</sup>                | 2021             | 2022             | Change      |
|----------------------------------------------------------------|------------------|------------------|-------------|
| Claims expense                                                 | (5,706.2)        | (5,954.4)        | 4.3%        |
| Risk equalisation                                              | (24.6)           | (36.1)           | 46.7%       |
| <b>Net resident claims expense</b>                             | <b>(5,730.8)</b> | <b>(5,990.5)</b> | <b>4.5%</b> |
| - Hospital                                                     | (4,247.2)        | (4,428.5)        | 4.3%        |
| - Extras                                                       | (1,483.6)        | (1,562.0)        | 5.3%        |
| <b>Average claims expense per policy unit<sup>2</sup> (\$)</b> | <b>(1,249.3)</b> | <b>(1,278.1)</b> | <b>2.3%</b> |
| Hospital claims per policy unit growth                         | 2.5%             | 2.7%             | 20bps       |
| Extras claims per policy unit growth                           | 3.9%             | 2.5%             | (140bps)    |
| Resident hospital utilisation growth <sup>3</sup>              | (0.1%)           | 0.4%             | 50bps       |
| Resident extras utilisation growth <sup>3</sup>                | 2.2%             | 1.8%             | (40bps)     |


## Average underlying claims growth per policy unit of 2.3% in line with expectations

- Lower extras claims growth following investment in additional product benefits in 1H21
- Modest increase in hospital claims growth due to a number of claims reduction initiatives in the prior period and mix impacts
- Public hospital claims more heavily impacted than private hospital claims due to more significant COVID-19 impacts on admissions
- Overall claims growth lower than individual hospital and extras growth due to relative costs, volume and growth

## Expect underlying claims per policy unit growth of 2.3% in FY23

- Given RE volatility, we expect underlying claims growth across the last 12 months of 2.3% to be the best indicator of growth in FY23
- Subject to prostheses reform savings
- Will continue to closely monitor rehab trends, emerging signs this could be a more permanent trend which could favourably impact future underlying claims growth

## Indicative composition & movement in dollar value<sup>1</sup> vs. FY21



<sup>1</sup> All numbers are in respect of the resident portfolio and on an underlying basis. See slide 35 for reconciliation of reported to underlying claims and COVID-19 impacts

<sup>2</sup> Based on an average of the month-end balances over the reporting period

<sup>3</sup> Actual hospital utilisation for FY21 was slightly below the reported estimate of (0.2%) as at 30 June 2021. Actual extras utilisation for FY21 was in line with the 2.2% reported estimate as at 30 June 2021. Estimated utilisation differs from actual utilisation largely as a result of the claims provision impacts

# Health Insurance – underlying portfolio performance

Well positioned for growth in FY23 with improved second half trajectory in non-resident business

| Financial year ended 30 June (\$m) <sup>1</sup> | Resident     |              |              | Non-resident |              |                 | Total        |              |              |
|-------------------------------------------------|--------------|--------------|--------------|--------------|--------------|-----------------|--------------|--------------|--------------|
|                                                 | 2021         | 2022         | Change       | 2021         | 2022         | Change          | 2021         | 2022         | Change       |
| Premium revenue                                 | 6,754.8      | 7,082.3      | 4.8%         | 151.5        | 146.9        | [3.0%]          | 6,906.3      | 7,229.2      | 4.7%         |
| Net hospital claims                             | [4,247.2]    | [4,428.5]    | 4.3%         | [103.0]      | [109.4]      | 6.2%            | [4,350.2]    | [4,537.9]    | 4.3%         |
| Extras claims                                   | [1,483.6]    | [1,562.0]    | 5.3%         |              |              |                 | [1,483.6]    | [1,562.0]    | 5.3%         |
| Net claims expense                              | [5,730.8]    | [5,990.5]    | 4.5%         | [103.0]      | [109.4]      | 6.2%            | [5,833.8]    | [6,099.9]    | 4.6%         |
| Gross profit – underlying                       | 1,024.0      | 1,091.8      | 6.6%         | 48.5         | 37.5         | [22.7%]         | 1,072.5      | 1,129.3      | 5.3%         |
| <b>Gross margin – underlying</b>                | <b>15.2%</b> | <b>15.4%</b> | <b>20bps</b> | <b>32.0%</b> | <b>25.5%</b> | <b>[650bps]</b> | <b>15.5%</b> | <b>15.6%</b> | <b>10bps</b> |
| Gross profit – reported                         | 1,034.0      | 1,091.2      | 5.5%         | 35.5         | 37.5         | 5.6%            | 1,069.5      | 1,128.7      | 5.5%         |
| Resident premium increase                       | 3.27%        | 3.22%        | (5bps)       | -            | -            | -               | 3.27%        | 3.22%        | (5bps)       |
| Downgrading                                     | [0.9%]       | [0.6%]       | 30bps        | -            | -            | -               | [0.6%]       | [0.3%]       | 30bps        |
| Revenue per policy unit growth rate             | 2.4%         | 2.6%         | 20bps        | 1.5%         | 6.1%         | 460bps          | 2.6%         | 2.9%         | 30bps        |
| Claims per policy unit growth rate              | 2.5%         | 2.3%         | (20bps)      | 11.6%        | 16.2%        | 460bps          | 3.1%         | 2.8%         | (30bps)      |
| Policy units (thousand)                         |              |              |              |              |              |                 |              |              |              |
| Closing balance                                 | 4,630.9      | 4,758.9      | 2.8%         | 180.6        | 196.5        | 8.8%            | 4,811.5      | 4,955.4      | 3.0%         |
| Average balance                                 | 4,587.3      | 4,687.1      | 2.2%         | 196.8        | 179.9        | [8.6%]          | 4,784.1      | 4,867.1      | 1.7%         |

## Underlying resident performance

### Strong policy unit growth

- Spot growth 60bps higher than growth in average balance

### Gross margin expansion of 20bps

- Improved revenue per policy unit
- Lower claims per policy unit

### Continued subdued downgrading of 60bps, down 30bps

- Benefit of Medibank policyholder trajectory, portfolio management initiatives and sales mix
- Current economic conditions, expect downgrading of 80bps in FY23

**Expect growth in underlying claims per policy unit to be 2.3% in FY23**

## Underlying non-resident performance

### Spot policy units increased 8.8%

- Strong growth late in 2H22
- Average balance down 8.6%

### Underlying gross profit down \$11.0m

- Reported gross profit up \$2.0m
- Increased student intake resulted in material improvement in 2H22 gross profit to \$22.5m (1H22: \$15.0m) as prior periods' tenure and mix impacts start to unwind

### Good momentum leading into FY23

- Improved 2H22 underlying gross margin of 29.2% (1H22: 21.5%)
- FY23 gross profit to be higher than FY21 with potential upside from worker and visitor market segments

# Health Insurance – management expenses

Benefits of scale and productivity agenda delivered a 30bps reduction in underlying MER to 7.4%

| Financial year ended 30 June (\$m) | 2021        | 2022        | Change         |
|------------------------------------|-------------|-------------|----------------|
| Premium revenue                    | 6,680.3     | 6,859.8     | 2.7%           |
| Management expenses                | (530.9)     | (536.1)     | 1.0%           |
| - Depreciation and amortisation    | (43.7)      | (40.4)      | (7.6%)         |
| - DAC amortisation                 | (39.3)      | (37.8)      | (3.8%)         |
| - Non-resident sales commissions   | (7.7)       | (13.9)      | 80.5%          |
| - Operating expenses <sup>1</sup>  | (440.2)     | (444.0)     | 0.9%           |
| <b>MER</b>                         | <b>7.9%</b> | <b>7.8%</b> | <b>(10bps)</b> |
| <b>Underlying MER</b>              | <b>7.7%</b> | <b>7.4%</b> | <b>(30bps)</b> |

## Management expenses increased 1.0%

- Productivity savings and lower non-cash costs
- Largely offset cost inflation and non-resident commissions

## Non-cash costs reduced by \$4.8m

- Lower D&A
- DAC decrease with progressive shifting of ahm to direct sales channels

## Non-resident sales commissions increased \$6.2m

- \$11.0m of sales commissions in 2H22 (1H22:\$2.9m)
- Expect a similar \$ increase in FY23 compared to FY22

## Delivered c. \$15m in productivity savings

- Savings from process improvement, increasing use of digital channels and flexible working
- On track to deliver \$40m between FY22 – FY24

## Operating expenses increased 0.9%

- Underlying cost inflation of c. 2.5%
- Additional statutory costs of c. \$2.0m
- Volume-related increases due to higher policyholders
- Largely offset by productivity

## Underlying MER declined 30 bps to 7.4%

- Increasing revenue
- Benefit of growth and scale

## FY23 operating expenses

- Expect cost inflation of 3.5% – 4.0%
- Inflation expected to be largely offset by productivity
- Leverage strong revenue growth and increasing scale to improve MER while balancing medium-term growth aspirations

<sup>1</sup> Includes right-of-use depreciation of \$23.4m (FY21: \$21.8m)

# Navigating the current macroeconomic environment

Well placed to manage a period of expected higher inflation

## Policyholder growth

---

### Industry growth expected to soften

- Expected to remain well above pre-pandemic levels
- Supported by continued community focus on health and wellbeing and public system challenges

### Factors expected to offset

- Continuation of low premium increases
- Implementation of Adult Dependent Reform
- Potential for further customer give backs
- Increased number of no gap services for customers

**FY25 market share growth aspiration: +25-75bps from FY22**

## Claims

---

### Importance of hospital contracting conversations

- Broadening set of outcomes
- Customer experience KPIs

### Factors expected to offset

- Next phase of prosthesis reform
- Monitor for permanent shift away from acute rehab
- Monitor spend in discretionary ancillary modalities which could be impacted by economic conditions

### Amplar providing more services to Medibank customers

- Increasing focus on prevention programs supported by Live Better and primary care
- Greater adoption of in home care
- Delivering integrated care models at scale

## Downgrading

---

### Modest deterioration in downgrading expected off a low base

- FY22: 60bps, FY23 outlook: 80bps

### Factors expected to offset

- Seven-month premium increase deferral
- Low premium increases thereafter
- Continued portfolio management initiatives

### Proactive approach to customers needs

- Enhance coverage of Right Cover program
- Continuation of hardship options

## Costs

---

### Increasing scale and industry leading MER

- Provides flexibility for organic growth
- Well-placed versus competitors

### Factors expected to offset

- PHI productivity program \$40m over FY22-FY24
- Continued cost discipline

### Opportunities to manage non-cash costs

- Increasing direct ahm sales
- Considered investments to manage D&A

**44.9% growth in segment profit including a meaningful uplift in the contribution from healthcare investments**

| Financial year ended 30 June (\$m)                         | 2021         | 2022         | Change          |
|------------------------------------------------------------|--------------|--------------|-----------------|
| Revenue                                                    | 283.8        | 321.8        | 13.4%           |
| Gross profit                                               | 117.0        | 129.2        | 10.4%           |
| Management expenses                                        | (84.8)       | (88.4)       | 4.2%            |
| <b>Operating profit</b>                                    | <b>32.2</b>  | <b>40.8</b>  | <b>26.7%</b>    |
| Share of profit/(loss) from Myhealth                       | 0.7          | 2.9          | n.m.            |
| Share of profit/(loss) from other investments <sup>1</sup> | (1.5)        | 1.8          | n.m.            |
| <b>Medibank Health segment profit</b>                      | <b>31.4</b>  | <b>45.5</b>  | <b>44.9%</b>    |
| <br>                                                       |              |              |                 |
| <b>Gross margin</b>                                        | <b>41.2%</b> | <b>40.1%</b> | <b>(110bps)</b> |
| MER                                                        | 29.9%        | 27.5%        | (240bps)        |
| <b>Operating margin</b>                                    | <b>11.3%</b> | <b>12.7%</b> | <b>140bps</b>   |

## Largely offsetting COVID-19 impacts

- Travel insurance impacted by closed borders
- Lockdowns impacted homecare patient numbers
- Largely offset by COVID-19 related services

## Segment profit increased by 44.9% to \$45.5m

- Operating profit up 26.7%
- \$4.7m contribution from healthcare investments (including a 12-month contribution from the Myhealth GP business)

## Revenue growth of 13.4%

- Strong growth in telehealth and health and wellbeing
- Recovery in travel insurance in 2H22
- Modest reduction in homecare due to seasonality and elective surgery restrictions

## Gross margin down 110bps to 40.1%

- Nurse wage inflation in homecare - expected to continue in FY23
- Transition out of 1800RESPECT and Beyond Blue contracts

## Management expenses up \$3.6m

- Includes \$2m of contract exit costs
- MER improved due to strong revenue growth – reinforces opportunity to create scale

## FY23 revenue and cost decline due to exit of 1800RESPECT and Beyond Blue in telehealth – immaterial impact on operating profit

## Expect ≥15% average organic segment profit growth p.a. over 3 years

- Strong momentum in remainder of Medibank Health
- Growth opportunity around the needs of Medibank customers
- Potential for further growth from M&A
- Prepared to invest for the long term

<sup>1</sup> Includes interest income from loan to associates FY21: \$0.2m, FY22: \$0.2m

# Investment portfolio and investment income

Investment income impacted by volatile markets but FY23 will benefit from increasing RBA cash rate

|                                                               | Reported performance <sup>2</sup> |                |                 | Underlying performance <sup>2</sup> |              |                 |
|---------------------------------------------------------------|-----------------------------------|----------------|-----------------|-------------------------------------|--------------|-----------------|
| Financial year ended 30 June (\$m)                            | 2021                              | 2022           | Change          | 2021                                | 2022         | Change          |
| <b>Net investment income:</b>                                 |                                   |                |                 |                                     |              |                 |
| Growth portfolio income                                       | 85.9                              | 2.9            | (96.6%)         | 41.3                                | 35.3         | (14.5%)         |
| Defensive portfolio income/(expense)                          | 38.4                              | (23.5)         | (161.1%)        | 22.3                                | 3.0          | (86.5%)         |
| <b>Fund portfolio investment income/(expense)<sup>1</sup></b> | <b>124.3</b>                      | <b>(20.6)</b>  | <b>(116.6%)</b> | <b>63.6</b>                         | <b>38.3</b>  | <b>(39.8%)</b>  |
| Net other investment income and expenses                      | (4.3)                             | (4.2)          | (2.3%)          | (4.3)                               | (4.2)        | (2.3%)          |
| <b>Total net investment income/(expense)</b>                  | <b>120.0</b>                      | <b>(24.8)</b>  | <b>(120.7%)</b> | <b>59.3</b>                         | <b>34.1</b>  | <b>(42.5%)</b>  |
| Investment returns on growth assets                           | 18.46%                            | 0.61%          | (1,785bps)      | 8.87%                               | 7.37%        | (150bps)        |
| Investment returns on defensive assets                        | 2.06%                             | (1.22%)        | (328bps)        | 1.20%                               | 0.16%        | (104bps)        |
| <b>Fund Portfolio investment returns</b>                      | <b>5.34%</b>                      | <b>(0.85%)</b> | <b>(619bps)</b> | <b>2.73%</b>                        | <b>1.59%</b> | <b>(114bps)</b> |
| RBA cash rate (average)                                       |                                   |                |                 | 0.15%                               | 0.18%        |                 |
| <b>Underlying spread to RBA cash rate</b>                     |                                   |                |                 | <b>2.58%</b>                        | <b>1.41%</b> | <b>(117bps)</b> |
| <b>Average monthly balance:</b>                               |                                   |                |                 |                                     |              |                 |
| Growth                                                        | 465.4                             | 479.0          | 2.9%            |                                     |              |                 |
| Defensive                                                     | 1,864.7                           | 1,929.5        | 3.5%            |                                     |              |                 |
| <b>Total Fund Portfolio</b>                                   | <b>2,330.1</b>                    | <b>2,408.5</b> | <b>3.4%</b>     |                                     |              |                 |

## Volatile markets significantly impacted returns this period with a \$24.8m loss

- Growth portfolio down \$83m with a correction in domestic and global equity markets
- Defensive portfolio loss includes credit spread impact (FY22: \$26.5m cost, FY21: \$16.1m benefit)

## Retained 20% growth and 80% defensive asset allocation

Underlying investment income adjusts for returns on growth assets relative to our long-term market return expectation of 8% and for credit spread movements

## Underlying investment income down \$25.2m to \$34.1m

- \$19.3m reduction in defensive portfolio, impacted by market liquidity and steepening interest rate curve
- Underlying spread to RBA cash rate of 141bps modestly below target range of 150 – 200bps per annum

## Underlying FY23 defensive portfolio income impacts

- RBA cash rate increases - each 25bps will increase investment income by c. \$5m
- Expect liquidity and steepening interest rate curve impacts will not be as significant as in FY22

<sup>1</sup> Excludes interest income from non health fund investments, short-term operational cash sub portfolio and operational cash

<sup>2</sup> Reported and underlying returns are calculated using total average monthly balances

# Capital and dividend

Total dividend increased 5.5% and payout at the top end of our target range

| Financial year ended 30 June (\$m)              | 2021           | 2022           |
|-------------------------------------------------|----------------|----------------|
| Total equity                                    | 1,906.1        | 1,945.6        |
| Less: Intangible and illiquid assets            | (445.3)        | (415.7)        |
| <b>Total tangible and liquid assets</b>         | <b>1,460.8</b> | <b>1,529.9</b> |
| Determined but unpaid ordinary dividend         | (190.0)        | (201.0)        |
| Cost of product bonus additions <sup>1</sup>    | (10.5)         | (10.0)         |
| <b>Total tangible eligible capital</b>          | <b>1,260.3</b> | <b>1,318.9</b> |
| Required capital                                |                |                |
| - Health Insurance                              | 942.0          | 983.7          |
| - Other                                         | 147.6          | 187.2          |
| Unallocated capital                             | 170.7          | 148.0          |
| <b>Health Insurance capital (%)<sup>2</sup></b> | <b>13.0%</b>   | <b>13.0%</b>   |

| Dividend                                      | 2021         | 2022         |
|-----------------------------------------------|--------------|--------------|
| Final ordinary dividend per share (cents)     | 6.9          | 7.3          |
| Full year ordinary dividend per share (cents) | 12.7         | 13.4         |
| <b>Dividend payout ratio<sup>3</sup></b>      | <b>87.7%</b> | <b>84.8%</b> |

## Health Insurance capital up \$41.7m

- Ratio at the top end of 11% to 13% target range<sup>2</sup>
- Increased due to premium revenue growth

## Other required capital increased by \$39.6m

- Investment in new hospital joint ventures
- \$10m investment in Medinet

## Unallocated capital down \$22.7m

- Reduction due to cost of investments
- Partially offset by disciplined capital management resulting in \$29.6m reduction in intangible and inadmissible assets

## New PHI capital standard to apply from 1 July 2023

- Not expected to negatively impact capital position
- Allows for issuance of Tier 2 debt
- Expect to provide update on capital settings at 1H23 result

## Strong capital position provides flexibility for further inorganic growth

- If suitable opportunities do not arise we will consider further capital management

## FY22 dividend of 13.4cps

- 84.8% payout ratio of Underlying NPAT (target range 75% - 85%)
- Final fully franked dividend of 7.3cps, up 5.8%

<sup>1</sup> Policies that include a product bonus receive an entitlement every 1 January to spend on otherwise uncovered expenses. The allowance is booked on 1 January each year

<sup>2</sup> Calculated as required Health Insurance related capital post dividends divided by the last 12 months' Health Insurance premium revenue inflated by the growth rate in Health Insurance premium revenue over the same 12-month period

<sup>3</sup> Dividend payout ratio is based on Underlying NPAT

# Key areas of growth for FY23 and beyond

A number of avenues for growth which further diversify earnings



## Maintain momentum in resident PHI

- Maintain policyholder growth and focus on increasing market share
- Target growth in priority segments including corporate and regional customers
- Manage operating margins
- Leverage cost benefits of scale



## Growth in non-resident PHI

- Leverage partnerships and capabilities to support growth
- Increase share among visitor and working visa health cover with borders reopening
- Consider other investment opportunities and avenues for growth



## Scale and expand Medibank Health

- Expect continued organic earnings growth -  $\geq 15\%$  average growth p.a. over 3 years
- Increase penetration of preventative programs including Live Better
- Deliver integrated care models at scale



## Inorganic growth

- Aim to invest \$150m to \$250m in total over the next 3 years, primarily in health and wellbeing, primary care and new care models (including additional short stay hospitals)
- Will review Health Insurance opportunities where targets are distressed



## Deliver synergies

- Provide more health services to Medibank members
- Support improved health experiences and retention



medibank

# Conclusion

**David Koczkar**  
Chief Executive Officer

# Supporting customers with their mental health journey

An example of our broad and unique capabilities

## Everyday wellbeing

### Live Better

- Access mental wellbeing through digital content, events, rewards and partnerships
- Live Better Reward members can redeem points with our health and wellbeing partners
- Deeply integrated into Medibank covers, with enhanced product benefits

### Smiling Mind app<sup>1</sup>

- Develop wellbeing skills



## Looking to take care of yourself

### Better Minds Hub

- Information and education

### Medibank Better Minds App

- Learn evidence-based cognitive behaviour therapy skills
- Book one-on-one coaching
- Integrated into Medibank hospital covers



## Looking for support

### 24/7 Medibank Mental Health Line

- Get support from qualified mental health professionals
- Offered to ahm customers as part of COVID support
- Services provided by Amplar

### Find a Provider

Search for details of Members' Choice providers, Members' Choice hospitals and GapCover specialists

### Enhanced benefits for mental health support

Available in eligible extra products (e.g. virtual psychology or counselling consultations)<sup>2</sup>



## Committing to professional support towards recovery

### Medibank Health Concierge

- Pre hospital support to help eligible customers prepare for a hospital stay or treatment
- Post hospital support for mental health in development
- Services provided by Amplar

### Telepsych clinic trial

- Aimed to provide greater access to primary mental health service
- Delivered by Amplar (including Medinet and Myhealth GPs)

### Community model of care

- Piloting new model of care for mental health in partnership with hospitals

## Better value cover

<sup>1</sup> Medibank is the Official Health Partner of Smiling Mind

<sup>2</sup> Benefits payable towards Medibank recognised Counsellors only

# We have multiple avenues for growth


Through sustaining competitive advantages in PHI and opportunities in health



## We will continue to do the right thing by our customers

---

- We have a dedicated and passionate team, and we are progressing our vision of the best health and wellbeing for Australia
  - We are well-positioned to continue to deliver a differentiated offering for our customers in health
  - We will continue to advocate for changes to create a more sustainable and affordable health system
- 



## We have good momentum leading into FY23

---

- Consumer sentiment supports continued industry growth, albeit at a slower rate
  - We have seen strong adoption by customers of our broader offerings in health
  - We have a track record of managing our business well in challenging circumstances
- 



## We remain focused on growing as a health company

---

- **Insurance:** through our dual brands which deliver more value, choice and control for customers
  - **Health:** by scaling and connecting our health businesses
  - **Delivering synergies:** by prioritising services directly to Medibank customers
  - **Flexibility:** our strong balance sheet and capital position provide flexibility to invest and partner in target markets
-



## Customer relief

- We continue to assess claims activity and any permanent net claims savings due to COVID-19 will be given back to customers through additional support in the future



## Policyholder growth

- c. 2.7% assuming a modest decline in industry participation growth in FY23 relative to FY22



## Claims

- Given risk equalisation volatility, we expect underlying net claims expense per policy unit growth in FY22 of 2.3% to be the best indicator of growth in FY23 among resident policyholders



## Management expense in PHI

- Productivity \$40m in FY22-FY24 (including c. \$15m delivered in FY22)
- Inflation expected to be largely offset by productivity



## Growth

- Targeted organic and inorganic growth for Medibank Health and Health Insurance remain areas of focus, supported by a strong capital position

# Appendix



# FY22 milestone scorecard

## Milestones<sup>1</sup>

## FY22 outcomes

### Delivering leading experience



#### Customer advocacy: Service NPS (average)

|          | FY21 | FY22 | FY22 benchmark <sup>2</sup> |
|----------|------|------|-----------------------------|
| Medibank | 37.1 | 45.3 | >35                         |
| ahm      | 43.0 | 42.4 | >35                         |

#### Employee advocacy: eNPS

|                       | FY21 | FY22 | FY22 benchmark <sup>3</sup> |
|-----------------------|------|------|-----------------------------|
| Place to work         | +30  | +27  | ≥+24                        |
| Products and services | +26  | +29  | ≥+19                        |

### Differentiate our insurance business



#### Net policyholder growth

| FY21 <sup>4</sup> | FY22           |
|-------------------|----------------|
| +3.5% / +64.3k    | +3.2% / +60.9k |

| Medibank brand <sup>4</sup> | Medibank brand |
|-----------------------------|----------------|
| +1.3% / +18.1k              | +1.9% / +26.6k |

#### FY22 target (updated February 2022)<sup>5</sup>

3.1-3.3%, including continued growth in the Medibank brand

#### Market share

| FY21   | Q3FY22                       | FY24 aspiration     |
|--------|------------------------------|---------------------|
| 27.31% | 27.35%<br>[+4bps since FY21] | up 25-75bps on FY21 |

#### Health Insurance productivity delivered

| FY21     | FY22     | FY22 – FY24 target            |
|----------|----------|-------------------------------|
| c. \$20m | c. \$15m | \$40m including \$15m in FY22 |

### Expand in health



#### Medibank Health<sup>6</sup>

| FY18    | FY22    | FY22 target                                                          |
|---------|---------|----------------------------------------------------------------------|
| \$47.3m | \$45.5m | Replace the reported FY18 \$30m operating profit of Garrison by FY22 |

#### Health and wellbeing

|                                                 | FY18    | FY22    | FY22 target |
|-------------------------------------------------|---------|---------|-------------|
| Customers engaged with Live Better <sup>7</sup> | c. 366k | c. 568k | c. 480k     |

<sup>1</sup> Milestones as presented in FY22. All new and continuing milestones are detailed throughout the remainder of the presentation

<sup>2</sup> Benchmark reflects sustaining service levels while continuing to digitise the service delivery model

<sup>3</sup> FY22 benchmarks are based on the global average adjusted for Australian healthcare and financial insurance industry context

<sup>4</sup> Adjusted for suspensions and reactivations occurring as the result of COVID-19

<sup>5</sup> Assumes slowing industry participation growth in FY22 relative to FY21

<sup>6</sup> Milestone updated to align with Medibank Health segment profit and to reflect FY21 statements that the temporary travel insurance earnings impact is expected to be largely offset by the contribution from investments in FY22

<sup>7</sup> Includes total customers who have engaged with our preventative health offering, including Live Better Rewards, Live Better Activities, preventative health programs and any new offerings developed during the reporting period

# Summary of FY22 ESG achievements and progress

Enabling the best health and wellbeing through embedding sustainability in our business

## FY22 key achievements<sup>1</sup>



### Customer health

- 55% growth in customers engaged with Live Better and preventative programs
- Better Minds, our information hub and app supporting mental health, attracted c. 79k users and app downloads



### Employee health

- Female representation of 44% Board members and 44% Group and Senior Executives
- Embedded Future Fit way of flexible working model- c. 85% of employees working flexibly
- Piloted a carers support program for employees caring for ageing parents or a loved one with a disability or chronic illness - overwhelming positive feedback



### Community health

- Progressed the 10-year commitment to loneliness with the launch of We Are Lonely Podcast, reaching c. 55k listeners
- Launched 5th Reconciliation Action Plan and 2nd Accessibility and Inclusion Plan
- \$971k allocated to health research across Medibank



### Environmental health

- Set robust short, medium and long-term Net Zero targets – details to be announced in our 2022 Sustainability Report in September 2022
- New Melbourne head office from late 2024 to be a 6 Star Green Star Design building with environmental sustainability embedded throughout the building process



### Governance

- Published our 1st Group Human Rights Policy, strengthening our commitment to upholding human rights across our business
- Collaborated with a group of hospital providers to run a pilot assessment to better understand the risk of modern slavery in their supply chains
- Refreshed ESG materiality assessment and undertook first external assurance of key ESG metrics

## Future focus

- Grow Live Better and preventative programs
- Expand out-of-hospital models of care for mental health
- Develop tailored employee value propositions to drive employee advocacy, attraction and retention
- Increase representation and engagement of Aboriginal and Torres Strait Islander employees and employees with disability
- Progress strategic roadmap for 10-year loneliness impact, including key community partnerships
- Build on our partnership with Parkrun and help them towards their goal of 900k annual participants by the end of 2025
- Progress Net Zero pathway activities
- Look for opportunities to collaborate with our health partners to address climate change across the broader health system
- Introduce human rights provisions into existing procurement contracts
- Target \$1 million per annum in Aboriginal and Torres Strait Islander business procurement spend each year by FY25


<sup>1</sup> For more details, refer to our 2022 Sustainability Report to be published in September 2022

# Live Better – everyday wellbeing proposition

## Activities and inspiration



- Free activities offered to broader public e.g. Smiling mind meditation, free fitness classes, Park Run sponsor
- Curated content to inspire e.g. articles, podcasts, healthy recipes
- 1.5m people participated in free Live Better community activities



medibank  
*Live Better*

## Live Better Rewards



- c. 522k Live Better Rewards participants
- The program is deeply integrated into Medibank extras and hospital covers
- Eligible customers rewarded by
  - Tracking healthy actions via Live Better and My Medibank app, or
  - Utilising Members' Choice Advantage network that is expanding to c. 2.6k locations in Q1FY23
- Retention benefits, e.g. c. 140 bps lapse improvement between Live Better Rewards users vs. non-Live Better members in the 25-45yo cohort

### Track



Track everyday healthy actions

- Eat Better
- Move Better
- Feel Better

### Earn



Earn enough credits to progress to the next level, or complete goals and challenges to earn Live Better points

Members can also earn Live Better points through our health & wellbeing partner network

### Redeem



Live Better Reward members can use points earned to redeem rewards, including

Save on their PHI covers

- \$200 premium reduction
- Increase extras limit up to \$200
- Reduce hospital excess by \$250

Save on products and services or get gift cards from health and wellbeing partners

# Reconciliation of reported to underlying claims and COVID-19 impacts

## COVID-19 impacts – Health Insurance

| Financial year ended 30 June (\$m)                   | 2021           | 2022           |
|------------------------------------------------------|----------------|----------------|
| Deferral of April 2020 premium increase <sup>2</sup> | 96.0           | -              |
| Customer suspensions                                 | 27.0           | -              |
| Giveback                                             | 103.0          | 194.6          |
| Deferral of April 2022 premium increase              | -              | 174.8          |
| <b>Total customer relief impact</b>                  | <b>226.0</b>   | <b>369.4</b>   |
| Resident hospital claims                             | (170.1)        | (251.8)        |
| Non-resident claims                                  | 13.1           | -              |
| Resident ancillary claims                            | (66.0)         | (117.0)        |
| <b>COVID-19 claims expense impacts</b>               | <b>(223.0)</b> | <b>(368.8)</b> |
| <b>Net COVID-19 impacts</b>                          | <b>3.0</b>     | <b>0.6</b>     |

## COVID-19 claims liability impacts

| Financial year ended 30 June 2022 (\$m)         | Hospital <sup>1</sup> | Ancillary      | Total          |
|-------------------------------------------------|-----------------------|----------------|----------------|
| 30 June 2021 – COVID-19 claims liability        | 220.2                 | 3.6            | 223.8          |
| Hindsight provision movement                    | (8.5)                 | (0.2)          | (8.7)          |
| Net (utilisation) / deferral during the period  | 193.9                 | 39.3           | 233.2          |
| <b>30 June 2022 – COVID-19 claims liability</b> | <b>405.6</b>          | <b>42.7</b>    | <b>448.3</b>   |
| (Lower) / higher than expected claims           | (437.2)               | (156.1)        | (593.3)        |
| Change to liability increase / (decrease)       | 185.4                 | 39.1           | 224.5          |
| <b>COVID-19 claims expense impacts</b>          | <b>(251.8)</b>        | <b>(117.0)</b> | <b>(368.8)</b> |

<sup>1</sup> Hospital includes non-resident

<sup>2</sup> April 2020 premium deferral accounted for over FY20 (\$65m) and FY21

## Reconciliation of reported to underlying claims

| Financial year ended 30 June (\$m)              | 2021             | 2022             |
|-------------------------------------------------|------------------|------------------|
| <b>Total reported claims</b>                    | <b>(5,610.8)</b> | <b>(5,731.1)</b> |
| COVID-19 claims expense impacts                 | (223.0)          | (368.8)          |
| <b>Total underlying claims</b>                  | <b>(5,833.8)</b> | <b>(6,099.9)</b> |
| <b>Underlying claims per policy unit growth</b> | <b>3.1%</b>      | <b>2.8%</b>      |

|                                                 |                  |                  |
|-------------------------------------------------|------------------|------------------|
| <b>Reported resident claims</b>                 | <b>(5,494.8)</b> | <b>(5,621.7)</b> |
| COVID-19 claims expense impacts                 | (236.0)          | (368.8)          |
| <b>Underlying resident claims</b>               | <b>(5,730.8)</b> | <b>(5,990.5)</b> |
| <b>Underlying claims per policy unit growth</b> |                  |                  |
| Total resident                                  | 2.5%             | 2.3%             |
| Hospital                                        | 2.5%             | 2.7%             |
| Extras                                          | 3.9%             | 2.5%             |

|                                                 |                |                |
|-------------------------------------------------|----------------|----------------|
| <b>Reported non-resident claims</b>             | <b>(116.0)</b> | <b>(109.4)</b> |
| COVID-19 claims expense impacts                 | 13.0           | -              |
| <b>Underlying non-resident claims</b>           | <b>(103.0)</b> | <b>(109.4)</b> |
| <b>Underlying claims per policy unit growth</b> | <b>11.6%</b>   | <b>16.2%</b>   |

# Group financial summary – half by half

| (\$m)                                        | 1H21           | 2H21           | 1H22           | 2H22           | Change         |                |               |
|----------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|---------------|
|                                              |                |                |                |                | 2H22 v 2H21    | 2H22 v 1H22    | 1H22 v 1H21   |
| <b>Group revenue from external customers</b> | <b>3,442.2</b> | <b>3,468.2</b> | <b>3,581.2</b> | <b>3,547.3</b> | <b>2.3%</b>    | <b>(0.9%)</b>  | <b>4.0%</b>   |
| Health Insurance operating profit            | 254.6          | 284.0          | 280.9          | 311.7          | 9.8%           | 11.0%          | 10.3%         |
| Medibank Health segment profit               | 18.8           | 12.6           | 25.7           | 19.8           | 57.1%          | (23.0%)        | 36.7%         |
| <b>Segment operating profit</b>              | <b>273.4</b>   | <b>296.6</b>   | <b>306.6</b>   | <b>331.5</b>   | <b>11.8%</b>   | <b>8.1%</b>    | <b>12.1%</b>  |
| Corporate overheads                          | (18.2)         | (23.5)         | (20.1)         | (23.9)         | 1.7%           | 18.9%          | 10.4%         |
| <b>Group operating profit</b>                | <b>255.2</b>   | <b>273.1</b>   | <b>286.5</b>   | <b>307.6</b>   | <b>12.6%</b>   | <b>7.4%</b>    | <b>12.3%</b>  |
| Net investment income/(expense)              | 71.8           | 48.2           | 30.9           | (55.7)         | n.m.           | n.m.           | (57.0%)       |
| Amortisation of intangibles                  | (3.4)          | (1.2)          | (1.0)          | (1.0)          | (16.7%)        | -              | (70.6%)       |
| Other income/(expenses)                      | (1.7)          | (9.7)          | (3.2)          | (4.1)          | (57.7%)        | 28.1%          | 88.2%         |
| <b>Profit before tax</b>                     | <b>321.9</b>   | <b>310.4</b>   | <b>313.2</b>   | <b>246.8</b>   | <b>(20.5%)</b> | <b>(21.2%)</b> | <b>(2.7%)</b> |
| Income tax expense                           | (95.5)         | (95.6)         | (93.0)         | (73.1)         | (23.5%)        | (21.4%)        | (2.6%)        |
| <b>NPAT</b>                                  | <b>226.4</b>   | <b>214.8</b>   | <b>220.2</b>   | <b>173.7</b>   | <b>(19.1%)</b> | <b>(21.1%)</b> | <b>(2.7%)</b> |
| EPS (cents)                                  | 8.2            | 7.8            | 8.0            | 6.3            | (19.1%)        | (21.1%)        | (2.7%)        |
| Normalisation for growth asset returns       | (13.2)         | (18.0)         | (7.4)          | 30.1           | n.m.           | n.m.           | (43.9%)       |
| Normalisation for defensive asset returns    | (9.8)          | (1.5)          | (0.4)          | 18.9           | n.m.           | n.m.           | (95.9%)       |
| <b>Underlying NPAT</b>                       | <b>203.4</b>   | <b>195.3</b>   | <b>212.4</b>   | <b>222.7</b>   | <b>14.0%</b>   | <b>4.8%</b>    | <b>4.4%</b>   |
| Underlying EPS (cents)                       | 7.4            | 7.1            | 7.7            | 8.1            | 14.0%          | 4.8%           | 4.4%          |
| <b>Dividend per share (cents)</b>            | <b>5.80</b>    | <b>6.90</b>    | <b>6.10</b>    | <b>7.30</b>    | <b>5.8%</b>    | <b>19.7%</b>   | <b>5.2%</b>   |
| Dividend payout ratio <sup>1</sup>           | 78.5%          | 97.3%          | 79.1%          | 90.3%          | (7.2%)         | 14.2%          | 0.8%          |

<sup>1</sup> Dividend payout ratio based on Underlying NPAT

# Health Insurance policyholders – half by half

|                                                     | 1H21           | 2H21           | 1H22           | 2H22           | Change         |               |                 |
|-----------------------------------------------------|----------------|----------------|----------------|----------------|----------------|---------------|-----------------|
|                                                     |                |                |                |                | 2H22 v 2H21    | 2H22 v 1H22   | 1H22 v 1H21     |
| <b>Premium revenue (\$m)</b>                        | <b>3,324.5</b> | <b>3,355.8</b> | <b>3,452.0</b> | <b>3,407.8</b> | <b>1.5%</b>    | <b>(1.3%)</b> | <b>3.8%</b>     |
| <b>Policyholders<sup>1</sup> (thousand):</b>        |                |                |                |                |                |               |                 |
| Opening balance                                     | 1,806.6        | 1,855.6        | 1,889.1        | 1,917.2        | 3.3%           | 1.5%          | 4.6%            |
| Acquisitions                                        | 102.6          | 118.6          | 106.2          | 116.8          | (1.5%)         | 10.0%         | 3.5%            |
| Lapses                                              | (62.8)         | (84.6)         | (78.1)         | (84.0)         | (0.7%)         | 7.6%          | 24.4%           |
| Net (suspensions)/reactivations                     | 9.2            | (0.5)          | -              | -              | n.m.           | n.m.          | n.m.            |
| Closing balance                                     | 1,855.6        | 1,889.1        | 1,917.2        | 1,950.0        | 3.2%           | 1.7%          | 3.3%            |
| - Medibank                                          | 1,405.8        | 1,417.8        | 1,429.9        | 1,444.4        | 1.9%           | 1.0%          | 1.7%            |
| - ahm                                               | 449.8          | 471.3          | 487.3          | 505.6          | 7.3%           | 3.8%          | 8.3%            |
| <b>Acquisition rate<sup>2</sup></b>                 | <b>5.6%</b>    | <b>6.3%</b>    | <b>5.6%</b>    | <b>6.0%</b>    | <b>(30bps)</b> | <b>40bps</b>  | <b>-</b>        |
| - Medibank                                          | 4.1%           | 4.9%           | 4.4%           | 4.8%           | (10bps)        | 40bps         | 30bps           |
| - ahm                                               | 11.3%          | 11.6%          | 9.6%           | 10.1%          | (150bps)       | 50bps         | (170bps)        |
| <b>Lapse rate<sup>2</sup></b>                       | <b>3.4%</b>    | <b>4.5%</b>    | <b>4.1%</b>    | <b>4.3%</b>    | <b>(20bps)</b> | <b>20bps</b>  | <b>70bps</b>    |
| - Medibank                                          | 3.3%           | 4.0%           | 3.6%           | 3.8%           | (20bps)        | 20bps         | 30bps           |
| - ahm                                               | 5.0%           | 6.9%           | 6.2%           | 6.5%           | (40bps)        | 30bps         | 120bps          |
| <b>Policyholder growth</b>                          | <b>2.7%</b>    | <b>1.8%</b>    | <b>1.5%</b>    | <b>1.7%</b>    | <b>(10bps)</b> | <b>20bps</b>  | <b>(120bps)</b> |
| <b>Total policy units<sup>1,3</sup> (thousand):</b> |                |                |                |                |                |               |                 |
| Closing balance                                     | 4,761.6        | 4,811.5        | 4,858.7        | 4,955.4        | 3.0%           | 2.0%          | 2.0%            |
| Average balance                                     | 4,736.5        | 4,789.7        | 4,835.5        | 4,898.6        | 2.3%           | 1.3%          | 2.1%            |

1 Consistent with reported industry data, policyholder numbers only include the resident portfolio whereas total policy units include both resident and non-resident portfolios

2 Consolidated lapse and acquisition rates exclude transfers of policyholders between ahm and Medibank at a combined brand level. Figures at brand level include these transfers.

Lapse and acquisition rates are based on the average of the opening and closing balances for the period

3 Based on an average of the month-end balances over the reporting period

# Investment portfolio

| As at 30 June 2022                         | Spot Balance (\$m) | Portfolio composition | Average Balance (\$m) | Average Balance Portfolio composition | Target asset allocation |
|--------------------------------------------|--------------------|-----------------------|-----------------------|---------------------------------------|-------------------------|
| Australian equities                        | 133.9              | 5.4%                  | 130.2                 | 5.4%                                  | 5.0%                    |
| International equities                     | 100.7              | 4.1%                  | 118.6                 | 4.9%                                  | 6.0%                    |
| Property                                   | 182.9              | 7.4%                  | 175.8                 | 7.3%                                  | 7.0%                    |
| Infrastructure                             | 57.2               | 2.3%                  | 54.4                  | 2.3%                                  | 2.0%                    |
| <b>Growth</b>                              | <b>474.7</b>       | <b>19.2%</b>          | <b>479.0</b>          | <b>19.9%</b>                          | <b>20.0%</b>            |
| Fixed income <sup>1,2</sup>                | 1,462.0            | 59.0%                 | 1,408.5               | 58.5%                                 | 60.0%                   |
| Cash <sup>3</sup>                          | 540.0              | 21.8%                 | 521.0                 | 21.6%                                 | 20.0%                   |
| <b>Defensive</b>                           | <b>2,002.0</b>     | <b>80.8%</b>          | <b>1,929.5</b>        | <b>80.1%</b>                          | <b>80.0%</b>            |
| <b>Total Fund (pre-STOC)</b>               | <b>2,476.7</b>     | <b>100.0%</b>         | <b>2,408.5</b>        | <b>100.0%</b>                         | <b>100.0%</b>           |
| Short-term operational cash <sup>4,6</sup> | 760.4              |                       | 468.1                 |                                       |                         |
| <b>Total Fund</b>                          | <b>3,237.1</b>     |                       | <b>2,876.6</b>        |                                       |                         |
| Non health fund investments <sup>5,6</sup> | 189.8              |                       | 174.3                 |                                       |                         |
| <b>Total investment portfolio</b>          | <b>3,426.9</b>     |                       | <b>3,050.9</b>        |                                       |                         |

1 Target asset allocation comprises floating rate notes and asset-backed investments (33.0% vs 33.0% in FY21) and other fixed income (27.0% vs 27.0% in FY21). The Fund's average credit duration is approximately 1.9 years, average interest rate duration is approximately 0.4 years, and the average credit rating is 'A'

2 For investment portfolio purposes, fixed income comprises fixed income securities (\$2,379.8 m), less reclassified cash with maturities between 3-12 months (\$541.4m), less non health fund fixed income securities (\$156.4m), less short-term operational cash fixed income securities (\$234.4m), plus cash allocated to the Fixed income portfolio (\$14.4m)

3 For investment portfolio purposes, cash comprises cash and cash equivalents (\$596.7m) plus cash with maturities between 3-12 months (\$541.4m), less non health fund investments (\$33.4m), less short-term operational cash (\$526.0m), less operational cash (\$24.3m) less cash allocated to the Fixed income portfolio (\$14.4m)

4 Short-term operational cash ("STOC") sub-portfolio of the fund's investment portfolio consists of short dated defensive assets with the purpose of funding the COVID-19 claims liability and customer giveback. Given the short-term nature of this portfolio, it is not subject to the existing SAA, TAA framework

5 The fund's SAA does not apply to the non health fund investment portfolio

6 Prior Comparative average balances for Short-term operational cash (\$468.1m) and Non health fund investments (\$174.3m)

| Term                 | Definition                                                                                                                                                  |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1H                   | Six months ended/ending 31 December of the relevant financial year                                                                                          |
| 2H                   | Six months ended/ending 30 June of the relevant financial year                                                                                              |
| ABS                  | Australian Bureau of Statistics                                                                                                                             |
| AMA                  | Australian Medical Association                                                                                                                              |
| APRA                 | Australian Prudential Regulation Authority                                                                                                                  |
| bps                  | Basis points (1.0% = 100 bps)                                                                                                                               |
| CAGR                 | Compound annual growth rate                                                                                                                                 |
| cps                  | Cents per share                                                                                                                                             |
| DAC                  | Deferred acquisition costs                                                                                                                                  |
| Downgrading          | The difference between the average premium rate rise and revenue growth per policy unit                                                                     |
| eNPS                 | Employee Net Promoter Score. A measure of the likelihood of an employee to recommend the company's products and services and the company as a place to work |
| EPS                  | Earnings per share                                                                                                                                          |
| ESG                  | Environmental, Social and Governance                                                                                                                        |
| Extras utilisation   | The number of services provided by ancillary providers per ancillary policy unit and includes a provision for IBNR and COVID-19                             |
| FY                   | Financial year ended/ending 30 June                                                                                                                         |
| FYTD                 | Financial year to date                                                                                                                                      |
| Health Insurance     | Includes both resident and non-resident                                                                                                                     |
| Hospital utilisation | The number of hospital admissions per hospital policy unit and includes a provision for IBNR and COVID-19                                                   |
| IBNR                 | Incurred but not reported                                                                                                                                   |
| Live Better          | A Medibank program to inspire people to lead a healthier and happier lifestyle, with tools and rewards (for eligible members) to motivate people            |
| NPAT                 | Net profit after tax                                                                                                                                        |

| Term                     | Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Members Choice Advantage | An enhanced network of ancillary providers where customers can enjoy better value on eligible extras services. Includes dental and optical providers, and from 1 July 2022, physiotherapy, chiropractic, podiatry, acupuncture and remedial massage                                                                                                                                                                                                                                                                                       |
| MER                      | Management expense ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| n.m.                     | Not meaningful                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| pcp                      | Prior corresponding period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PHI                      | Private Health Insurance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Non-resident             | Overseas students health cover (OSHC) and Overseas visitors cover (OVC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Policyholder             | The primary person who is insured under a private health insurance policy (other than in relation to overseas students or visitors), who is not a dependent child, and who is responsible for paying the premium                                                                                                                                                                                                                                                                                                                          |
| PSEUs or policy units    | Policy Single Equivalent Units are used by Medibank as a standard measure of income units. They take into account the number of adults on a policy, and whether they have Hospital Cover or Extras Cover or both. For example, a household with two parents and three children, all of which had both Hospital and Extras Cover, would represent four policy units (2 adults x 2 types of Cover = 4). This measure includes residents and non-resident policies and only adult insureds are typically counted in the calculation of PSEUs |
| Resident                 | Hospital and/or extras cover for a compliant health insurance product                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| SAA                      | Strategic Asset Allocation. The long-term portfolio asset allocation that meets the expected risk and return objectives of the fund                                                                                                                                                                                                                                                                                                                                                                                                       |
| Service NPS              | A measure of the likelihood of an existing customer to recommend the brand immediately following a service interaction                                                                                                                                                                                                                                                                                                                                                                                                                    |
| TAA                      | Tactical Asset Allocation. The medium-term portfolio asset allocation that varies to the strategic asset allocation in order to help optimise risk-adjusted investment returns in light of the prevailing relative market pricing                                                                                                                                                                                                                                                                                                         |
| Underlying NPAT          | Underlying NPAT is calculated based on statutory NPAT adjusted for short-term outcomes that are expected to normalise over the medium to longer term, most notably in relation to the level of gains or losses from investments and movements in credit spreads, and for one-off items, especially those that are non-cash, such as asset impairments. Underlying NPAT is not adjusted for outstanding claims provision movements or COVID-19 impacts                                                                                     |
| Underlying               | Underlying figures (excluding Underlying NPAT, Underlying EPS and Underlying investment performance and income) are reported figures adjusted for outstanding claims provision movements and COVID-19 impacts                                                                                                                                                                                                                                                                                                                             |